Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells
- PMID: 35313445
- PMCID: PMC8925144
- DOI: 10.1016/j.jksus.2022.101965
Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells
Abstract
Objectives: The COVID-19 was identified for the first time from the sea food market, Wuhan city, China in 2019 and the pathogenic organism was identified as SARS-CoV-2. Currently, this virus has spread to 223 countries and territories and known as a serious issue for the global human community. Many vaccines have been developed and used for immunization.
Methods: We have reported the insilico prediction, designing, secondary structure prediction, molecular docking analysis, and in vitro assessment of siRNAs against SARS-CoV-2. The online bioinformatic approach was used for siRNAs selection and designing. The selected siRNAs were evaluated for antiviral efficacy by using Lipofectamine 2000 as delivery agent to HEK-293 cells. The MTT assay was used for cytotoxicity determination. The antiviral efficacy of potential siRNAs was determined based on the Ct value of q-RT-PCR and the data analysis was done by Prism-GraphPad software.
Results: The analyzed data resulted in the selection of only three siRNAs out of twenty-six siRNAs generated by online software. The secondary structure prediction and molecular docking analysis of siRNAs revealed the efficient binding to the target. There was no cellular toxicity observed in the HEK-293 cells at any tested concentrations of siRNAs. The purification of RNA was completed from inoculated cells and subjected to q-RT-PCR. The highest Ct value was observed in siRNA 3 than the others. The results offered valuable evidence and invigorated us to assess the potency of siRNAs by using alone or in combination in other human cells.
Conclusion: The data generated from this study indicates the significance of in silico prediction and narrow down the potential siRNA' against SARS-CoV-2, and molecular docking investigation offered the effective siRNAs binding with the target. Finally, it is concluded that the online bioinformatics approach provided the prediction and selection of siRNAs with better antiviral efficacy. The siRNA-3 was observed to be the best for reduction of viral RNA in cells.
Keywords: COVID-19, The new Coronavirus Disease 2019; Designing; HEK-293 cells; In silico prediction; MFE, Minimum free energy; PCR, Polymerase Chain Reaction; RNAi, RNA interference; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coranavirus-2; WHO, World Health Organization; siRNA, short interfering RNA; siRNAs.
© 2022 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures





Similar articles
-
In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells.J King Saud Univ Sci. 2022 Jun;34(4):102049. doi: 10.1016/j.jksus.2022.102049. Epub 2022 Apr 26. J King Saud Univ Sci. 2022. PMID: 35493709 Free PMC article.
-
Designing and evaluation of MERS-CoV siRNAs in HEK-293 cell line.J Infect Public Health. 2021 Feb;14(2):238-243. doi: 10.1016/j.jiph.2020.12.018. Epub 2020 Dec 29. J Infect Public Health. 2021. PMID: 33493920 Free PMC article.
-
Delivery of siRNAs against MERS-CoV in Vero and HEK-293 cells: A comparative evaluation of transfection reagents.J King Saud Univ Sci. 2023 Apr;35(3):102540. doi: 10.1016/j.jksus.2023.102540. Epub 2023 Jan 5. J King Saud Univ Sci. 2023. PMID: 36624781 Free PMC article.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
-
Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.Curr Pharm Des. 2018;24(1):62-77. doi: 10.2174/1381612823666171109112307. Curr Pharm Des. 2018. PMID: 29119921 Review.
Cited by
-
RNAi-Induced Gene Silencing against Chikungunya and COVID-19: What Have We Learned So Far, and What Is the Way Forward?Viruses. 2024 Sep 20;16(9):1489. doi: 10.3390/v16091489. Viruses. 2024. PMID: 39339965 Free PMC article. Review.
-
Research in the Field of Drug Design and Development.Pharmaceuticals (Basel). 2023 Sep 11;16(9):1283. doi: 10.3390/ph16091283. Pharmaceuticals (Basel). 2023. PMID: 37765091 Free PMC article. Review.
-
Biochemistry-informed design selects potent siRNAs against SARS-CoV-2.RNA Biol. 2023 Jan;20(1):272-280. doi: 10.1080/15476286.2023.2217400. RNA Biol. 2023. PMID: 37272117 Free PMC article.
-
Novel DNA Biosensing Platform for Detecting HIV Integrase for Highly Sensitive and Quantitative HIV Detection, Diagnosis, and Therapeutic Monitoring.ACS Omega. 2024 May 28;9(23):25042-25053. doi: 10.1021/acsomega.4c02229. eCollection 2024 Jun 11. ACS Omega. 2024. PMID: 38882085 Free PMC article.
References
-
- Alnylam Pharmaceuticals, 2020. Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including Covid-19. Available online at: https://investors.alnylam.com/press-release?id= 24656.
-
- Aleem, et al. Stat Pearls Publishing; In Stat Pearls: 2022. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) - PubMed
-
- Azoulay E., Fartoukh M., Darmon M., Géri G., Voiriot G., Dupont T., Zafrani L., Girodias L., Labbé V., Dres M., Beurton A., Vieillard-Baron A., Demoule A. Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. Intensive Care Med. 2020;46(9):1714–1722. - PMC - PubMed
-
- Bellaousov et al., 2013. RNA structure: Web servers for RNA secondary structure prediction and analysis. Nucl. Acids Res., 41(Web Server issue), W471–W474. https://doi.org/10.1093/nar/gkt290. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous